2006 Sales of Antibodies & Proteins

The present FREE Download contains a compilation of the 2006 sales of recombinant biologic products including antibodies, proteins and peptides. The report provides an overview of the 20 best selling biologics (TOP 20 Biologics) and 2006 sales for each class of biologics as well as for some selected biologics.

TOP 20 Biologics Sales

The sales of the 20 best selling antibodies and proteins in 2006 are listed up, each of them posting more than US$ 1 bln sales in 2006..

Therapeutic Proteins Sales

The report compiles 2006 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).

Erythropoietin

2006 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon and Epogin.

Insulin & Insulin Analogs

2006 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi-Aventis are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.

Coagulation Factors

2006 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer Schering Pharma, CSL Behring, Baxter and Wyeth are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto, Benefix (nonacog).

Interferon alpha and beta

2006 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron from Biogen Idec, Merck Serono and Bayer Schering Pharma as well as for Pegasys, Peg-Intron and Intron A from Roche and Schering-Plough.

Granulocyte Colony-Stimulating Factor (G-CSF)

2006 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim) and Neutrogin (lenograstim) from Amgen, Kirin and Chugai.

Human Growth Hormone (hGH)

2006 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen / Serostim from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono.

Enzyme Replacement Therpay (ERT)

2006 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa) and Naglazyme (galsulfase) from Genzyme, Biomarin, Shire and Dainippon Sumitomo.

Follicle Stimulating Hormone (FSH)

2006 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Organon.

Therapeutic Antibodies Sales

The report compiles 2006 sales of the major therapeutic antibodies per class: cancer antibodies targeting CD20, Her2, VEGF and EGF-R, anti-TNF antibodies and antiviral antibody.

Cancer Antibodies

2006 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab) from Genentech / Roche, Bristol-Myers Squibb, Merch Serono, Imclone and Amgen.

Anti-TNF Antibodies

2006 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott and Eisai.

Antiviral Antibody

2006 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune and Abbott International (Ross Division) are presented.

Selected Other Biologics

2006 sales of selected biologics (antibodies, proteins and peptides) are presented including the PTH products Forteo (teriparatide) and Preotact / Preos from Eli Lilly and NPS Pharmaceuticals / Nycomed, the GLP-1 analog Byetta (exenatide) from Eli Lilly and Amylin Pharmaceuticals, the VEGF targeting antibody fragment Lucentis (ranibizumab) for treatment of AMD from Genentech / Roche & Novartis, and the human growth factor rhBMP2 Inductos from Wyeth.

Table of Content

• Top 20 Blockbusters
• Top Selling Classes of Biological Products
• Growth Rates (2006 vs 2005)
• EPOs
• Cancer Antibodies
• Anti-TNF Biologics
• Insulin Products
• Rec. Coagulation Factors
• Interferon beta
• G-CSF
• human Growth Hormone
• Interferon alfa
• Enzyme Replacement
• Antiviral Antibody
• Follicle Stimulating Hormones
• Selected Other Biologics

#	Product Name	Target	Product Class	Company	Indication	2006 Sales (mln)
1	Enbrel / Embrel; etanercept	TNF-alpha	Fusion protein of Fc + sol TNF-R	Amgen & Wyeth & Takeda	Rheumatoid arthritis; psoriasis etc	US$ 4,474
2	Aranesp	EPO-R	Rhu darbepoetin alfa	Amgen	Renal and cancer anemia	US$ 4,121
3	Rituxan / MabThera; rituximab	CD20	Rec chimeric mab	Genentech/ Roche /Chugai Biogen IDEC, Zenyaku Kogyu	1 st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy	US$ 3,912
4	Remicade; infliximab	TNF-alpha	Rec chimeric mab	Centocor (J&J) & Schering-Plough & Tanabe Seiyaku	Rheumatoid arthritis etc	US$ 3,764
5	Procrit / Eprex	EPO-R	Rhu epoetin alfa	Johnson & Johnson	Renal and cancer anemia	US$ 3,180
6	Herceptin, trastuzumab	HER2	Rec humanized mab	Roche / Genentech	Metastatic breast cancer	US$ 3,175
7	Epogen / ESPO	EPO-R	Rhu epoetin alfa	Amgen & Kirin	Renal and cancer anemia	US$ 2,844
8	Neulasta; pegfilgrastim	CSF-receptor	Pegylated G-CSF	Amgen	Neutropenia	US$ 2,710
9	Actrapid / Novolin; Insulatard; Mixtard	Insulin receptor	Rhu insulin and related products	NovoNordisk	Diabetes	US$ 2,653
10	Avastin; bevacizumab	VEGF	Rec humanized mab	Roche & Genentech	Metastatic colorectal cancer	US$ 2,395
11	Lantus; insulin glargine	Insulin receptor	Rhu insulin analog	Sanof i Aventis	Diabetes mellitus	US$ 2,188
12	Humira; adalimumab	TNF-alpha	Rec fully human mab	Abbott (& Eisai)	Rheumatoid arthritis, psoriasis etc	US$ 2,044
13	Levemir; NovoLog (Mix)	Insulin receptor	Rhu insulin analogues aspart and detemir	Novo Nordisk	Diabetes	US$ 1,908
14	Neo-recormon / Epogin	EPO-R	Rhu epoetin beta	Roche & Chugai	Renal and cancer anemia	US$ 1,794
15	Avonex; inteferon beta-1a	IFN-R	Rhu interferon ß-1a	Biogen Idec	Multiple sclerosis	US$ 1,707
16	Rebif; interferon beta-1a	IFN-R	Rhu interferon ß-1a	Merck Serono	Multiple sclerosis	Full year estimate of US$ 1,418
17	Neupogen / GRAN; filgrastim	G-CSF-receptor	rhu G-CSF	Amgen & Kirin	Neutropenia	US$ 1,344
18	Humalog; insulin lispro	Insulin receptor	Rhu insulin analog	Eli Lilly	Diabetes	US$ 1,300
19	Betaferon / Betaseron; interferon beta-1b	IFN-R	Rhu interferon ß-1b	Bayer Schering Pharma	Multiple sclerosis	Full year estimate of US$ 1,273
20	Pegasys; peginterfer-on alfa-2a	IFN-R	Pegylated rec hu interferon	Roche	Hepatitis B and C	US$ 1,186

Related Competitor Analysis

• EPO
• VEGF and VEGF-R Agonists, Antagonists and Inhibitors
• TNF Antagonists
• Insulin
• Coagulation Factors
• Interferon
• G-CSF and GM-CSF
• Human Growth Hormone (hGH)
• Follicle Stimulating Hormone (FSH)
• GLP-1 Analogs
• Psoriasis
• Wet Age-Related Macular Degeneration (AMD)